AVN 63.94 Decreased By ▼ -1.02 (-1.57%)
BAFL 29.95 Decreased By ▼ -0.30 (-0.99%)
BOP 4.64 No Change ▼ 0.00 (0%)
CNERGY 3.88 No Change ▼ 0.00 (0%)
DFML 13.40 Decreased By ▼ -0.15 (-1.11%)
DGKC 40.64 Decreased By ▼ -1.56 (-3.7%)
EPCL 47.01 Increased By ▲ 1.20 (2.62%)
FCCL 10.99 Decreased By ▼ -0.42 (-3.68%)
FFL 5.05 Decreased By ▼ -0.12 (-2.32%)
FLYNG 5.76 Decreased By ▼ -0.04 (-0.69%)
GGL 9.78 Decreased By ▼ -0.26 (-2.59%)
HUBC 61.85 Decreased By ▼ -1.45 (-2.29%)
HUMNL 5.66 Decreased By ▼ -0.09 (-1.57%)
KAPCO 27.52 Decreased By ▼ -0.31 (-1.11%)
KEL 2.14 Increased By ▲ 0.01 (0.47%)
LOTCHEM 24.23 Decreased By ▼ -1.10 (-4.34%)
MLCF 20.78 Decreased By ▼ -0.79 (-3.66%)
NETSOL 83.19 Decreased By ▼ -1.80 (-2.12%)
OGDC 86.27 Increased By ▲ 0.04 (0.05%)
PAEL 10.78 Decreased By ▼ -0.14 (-1.28%)
PIBTL 4.11 Decreased By ▼ -0.12 (-2.84%)
PPL 76.26 Decreased By ▼ -2.26 (-2.88%)
PRL 13.66 Increased By ▲ 0.04 (0.29%)
SILK 0.88 Decreased By ▼ -0.01 (-1.12%)
SNGP 40.86 No Change ▼ 0.00 (0%)
TELE 5.87 Decreased By ▼ -0.13 (-2.17%)
TPLP 15.61 Decreased By ▼ -0.39 (-2.44%)
TRG 109.97 Decreased By ▼ -1.73 (-1.55%)
UNITY 13.80 Decreased By ▼ -0.19 (-1.36%)
WTL 1.14 Increased By ▲ 0.01 (0.88%)
BR100 3,967 Decreased By -58.9 (-1.46%)
BR30 14,185 Decreased By -217.7 (-1.51%)
KSE100 39,871 Decreased By -579.3 (-1.43%)
KSE30 14,898 Decreased By -212.2 (-1.4%)
Business & Finance

Moderna taps Baxter to support fill and finish of 60-90mn COVID-19 vaccine doses

  • Moderna's two-shot vaccine is one of the three COVID-19 vaccines authorized for emergency use in the United States along with Pfizer/BioNTech and Johnson & Johnson's.
  • Under the pact with Baxter, the fill and finish of Moderna COVID-19 vaccine will take place at the sterile manufacturing facilities located in Bloomington, Indiana, the companies said.
Published March 8, 2021
Follow us

Drugmaker Baxter International Inc will help fill in vials and package about 60-90 million doses of Moderna Inc's COVID-19 vaccine in 2021, the companies said on Monday.

Moderna's two-shot vaccine is one of the three COVID-19 vaccines authorized for emergency use in the United States along with Pfizer/BioNTech and Johnson & Johnson's .

Moderna, which expects to make 700 million to 1 billion doses of its vaccine this year, said in February that supply to the United States had lagged recently because of "short-term delays" in the final stages of production at its contractor Catalent Inc.

The company had signed a pact with Catalent last year to help support filling and packaging vials with its vaccine.

Under the pact with Baxter, the fill and finish of Moderna COVID-19 vaccine will take place at the sterile manufacturing facilities located in Bloomington, Indiana, the companies said.

Fill and finish is the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping.

Baxter has also partnered with Novavax Inc to provide sterile manufacturing services for its COVID-19 vaccine candidate.

Details on other terms of the pact with Moderna were not disclosed.

Comments

Comments are closed.

Moderna taps Baxter to support fill and finish of 60-90mn COVID-19 vaccine doses

Rupee closes at fresh low of 269.63 against US dollar as the great fall continues

KSE-100 falls over 500 points in aftermath of Peshawar blast

Pakistan facing adverse consequences of Ukraine conflict: FM Bilawal

Islamabad Court sends Fawad to jail on judicial remand

UAE president’s visit to Islamabad postponed over ‘bad weather’

Inflation to cross 30% as rupee depreciation, petrol prices bite: report

Oil steadies as rate hikes loom, Russian flows stay strong

Sheikh Rashid’s Lal Haveli residence sealed over ‘illegal occupation’

Asif Ali Zardari sends legal notice to Imran Khan over ‘assassination’ remarks

Abu Dhabi’s IHC plans to invest $381mn in Adani Enterprises